tailieunhanh - Báo cáo hóa học: "Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions"

Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions | Yang et al. Journal of Translational Medicine 2010 8 75 http content 8 1 75 RESEARCH JOURNAL OF TRANSLATIONAL MEDICINE Open Access Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions 1 71 2 1 3 4 1 2 Wan-Zhang Yang Yun Zhang Fang Wu Wei-Ping Min Boris Minev Min Zhang Xiao-Ling Luo Famela Ramos5 Thomas E Ichim5 Neil H Riordan5t Xiang Hu 2 t Abstract Background The current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease GVHD . Immunological arguments and historical examples have been made that the use of cord blood for non-hematopoietic activities such as growth factor production stimulation of angiogenesis and immune modulation may not require matching or immune suppression. Methods 114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched allogeneic cord blood. Doses of 1-3 X 107 cord blood mononuclear cells per treatment with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological immunological and biochemical parameters were analyzed for safety evaluation. Results No serious adverse effects were reported. Hematological immunological and biochemical parameters did not deviate from normal ranges as a result of therapy. Conclusion The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients. Background Cord blood mononuclear cells are comprised of a heterogenous population of hematopoietic and mesenchymal stem cells endothelial progenitor cells and immature immunological cells 1 2 . The conventional medical use of cord blood is limited to hematopoietic reconstitution 3 with clinical trials ongoing in type I diabetes 4 and cerebral palsy 5 . Preclinical studies have .